21 results on '"Sumiyoshi N"'
Search Results
2. P095 Accelerated degradation of gut barrier-protecting 3-aminobenzoic acid exacerbate colitis in Inflammatory Bowel Disease
- Author
-
Tanaka, M, primary, Toyonaga, T, additional, Nakagawa, F, additional, Sumiyoshi, N, additional, Shibuya, N, additional, Iwamoto, T, additional, Minemura, A, additional, Ariyoshi, T, additional, Matsumoto, A, additional, Oka, K, additional, Shimoda, M, additional, and Saruta, M, additional
- Published
- 2024
- Full Text
- View/download PDF
3. P001 MicroRNA-155-5p contributes to the development of Ulcerative Colitis by regulating T lymphocyte proliferation and functions
- Author
-
Sumiyoshi, N, primary, Toyonaga, T, additional, Shumway, A, additional, Nakagawa, F, additional, Tanaka, M, additional, Saeki, C, additional, Furey, T, additional, Sheikh, S, additional, Sethupathy, P, additional, and Saruta, M, additional
- Published
- 2024
- Full Text
- View/download PDF
4. LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
- Author
-
Lee, J-S., primary, Sugawara, S., additional, Kang, J.H., additional, Kim, H.R., additional, Inui, N., additional, Hida, T., additional, Lee, K.H., additional, Yoshida, T., additional, Tanaka, H., additional, Yang, C.T., additional, Nishio, M., additional, Ohe, Y., additional, Tamura, T., additional, Yamamoto, N., additional, Yu, C-J., additional, Akamatsu, H., additional, Namba, Y., additional, Sumiyoshi, N., additional, and Nakagawa, K., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Considerations for simultaneous detection of autoantibodies to coagulation factor and lupus anticoagulant
- Author
-
Masahiro Ieko, Kazumasa Ohmura, Sumiyoshi Naito, Mika Yoshida, Hisaomi Sasaki, Tsuyoshi Sato, Norifumi Sugawara, Nobuhiko Takahashi, and Akitada Ichinose
- Subjects
lupus anticoagulant-hypoprothrombinemia syndrome ,autoimmune coagulation factor deficiency ,lupus anticoagulant-hypoprothrombinemia syndrome-v ,acquired hemophilia a ,lupus anticoagulant ,thrombosis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
In patients with autoimmune coagulation factor deficiency (AiCFD), the production of autoantibodies that inhibit coagulation factors in the blood reduces the activity of those relevant coagulation factors, resulting in severe bleeding symptoms. Recently, reports of patients with AiCFD have noted the concomitant detection of lupus anticoagulant (LA), a risk factor for thrombosis. LA-positive patients may show bleeding symptoms due to decreased activity of coagulation factor II (FII) caused by autoantibodies against FII, in addition to thrombotic symptoms, a condition termed LA-hypoprothrombinemia syndrome (LAHPS). Anti-FII antibodies in LAHPS cases are frequently cleared antibodies that can be detected using immunological techniques, such as enzyme-linked immunosorbent assay (ELISA). Recently, several cases of coagulation FV inhibitors, known as autoimmune FV deficiency, have been reported. Some of these cases may be complicated by LA, which can cause thrombosis. False-positive results for anticoagulant inhibitors are known to occur in LA cases; therefore, immunological confirmation of antibodies against coagulation factors is recommended. Additionally, acquired hemophilia A (AHA), caused by autoantibodies against FVIII, is a typical acquired hemorrhagic diathesis, although affected patients may present with thrombosis associated with LA. Thus, it is important to remember that hemorrhagic diathesis due to autoantibodies against clotting factors can also result in thrombosis, as demonstrated by the co-detection of LA. When clotting factor inhibitors are detected in LA-positive individuals, it is important to confirm the presence of autoantibodies against coagulation factors using immunological methods, such as ELISA, to avoid false-positive results.
- Published
- 2023
- Full Text
- View/download PDF
6. The relationship between central motor conduction time and spinal cord compression in patients with cervical spondylotic myelopathy
- Author
-
Rikita, T, primary, Tanaka, N, additional, Nakanishi, K, additional, Kamei, N, additional, Sumiyoshi, N, additional, Kotaka, S, additional, Adachi, N, additional, and Ochi, M, additional
- Published
- 2016
- Full Text
- View/download PDF
7. Resection of spinous processes can cause spinal cord injury in patient with ossification of the posterior longitudinal ligament in the thoracic spine
- Author
-
Nakanishi, K, primary, Tanaka, N, additional, Kamei, N, additional, Hiramatsu, T, additional, Ujigo, S, additional, Sumiyoshi, N, additional, Rikita, T, additional, Takazawa, A, additional, and Ochi, M, additional
- Published
- 2014
- Full Text
- View/download PDF
8. The relationship between central motor conduction time and spinal cord compression in patients with cervical spondylotic myelopathy
- Author
-
Rikita, T, Tanaka, N, Nakanishi, K, Kamei, N, Sumiyoshi, N, Kotaka, S, Adachi, N, and Ochi, M
- Abstract
Study design:Retrospective study.Objectives:Few studies have reported a relationship between central motor conduction time (CMCT), which evaluates corticospinal function, and degree of spinal cord compression in patients with myelopathy. Thus, there is no consensus on predicting the degree of prolonged CMCT on the basis of the degree of spinal cord compression. If a correlation exists between CMCT and spinal cord compression, then spinal cord compression may be a useful noninvasive clinical indicator of corticospinal function. Therefore, this study evaluated the relationship between CMCT and cervical spinal cord compression measured by magnetic resonance imaging (MRI) in patients with cervical spondylotic myelopathy (CSM).Setting:Hiroshima University Hospital in Japan.Methods:We studied 33 patients undergoing laminoplasty. Patients exhibited significant cervical spinal cord compression on both MRI and intraoperative electrophysiological examination. We assessed transcranial magnetic stimulation measurement of CMCT; spinal cord compression parameters such as area, lateral diameter, anteroposterior diameter and flattening of the spinal cord at the lesion site and C2/3 levels on MRI; and pre- versus postoperative Japanese Orthopaedic Association (JOA) scores.Results:Correlations between CMCT and flattening as well as anteroposterior diameter of the spinal cord at the lesion level were observed. Strong correlations between CMCT and the ratio of the flattening and anteroposterior diameter parameters at the lesion level to that at the C2/3 level were also observed.Conclusions:Measurement of spinal cord compression may be useful for the evaluation of corticospinal function as a proxy for CMCT in patients with CSM.
- Published
- 2017
- Full Text
- View/download PDF
9. Endoscopic healing is associated with a reduced risk of biologic treatment failure in patients with ulcerative colitis.
- Author
-
Komatsu A, Toyonaga T, Sumiyoshi N, Tanaka M, Shibuya N, and Saruta M
- Subjects
- Humans, Retrospective Studies, Colonoscopy, Treatment Failure, Severity of Illness Index, Intestinal Mucosa, Colitis, Ulcerative drug therapy, Biological Products therapeutic use
- Abstract
Increasing number of patients with ulcerative colitis (UC) have received biologic treatment during the last decade. The association between endoscopic healing (EH) and biologic treatment failure remains understudied. Medical information of UC patients who started biologic treatment was retrospectively collected. EH was defined as Mayo endoscopic subscore of 0 or 1. Loss of response (LOR)-free drug continuation rate was compared between patients who achieved EH and those who did not using Kaplan-Meier estimator. Fifty-two patients received 53 biologic treatments and underwent follow-up colonoscopies within 2 years. Thirty-three patients achieved EH, all of which remained on the same treatment without LOR during the observational period. Twenty patients did not achieve EH, 8 of which ultimately discontinued the treatment due to LOR to biologic agents. Kaplan-Meier estimator found a significantly lower drug continuation rate in patients without EH (p < 0.001; log-rank test). A Cox regression analysis identified EH as an independent factor associated with a reduced risk of LOR-related biologic treatment failure irrespective of the types of biologic agents (Hazard Ratio = 0.0324, p < 0.001). EH within 2 years is associated with a reduced risk of LOR-related biologic treatment failure in patients with UC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
10. Small-head metal on metal total hip arthroplasty is associated with a high rate of complication and reoperation at mid-term follow-up.
- Author
-
Sumiyoshi N, Oinuma K, and Miura Y
- Abstract
Background: Adverse reactions to metal debris are significant complications after metal-on-metal total hip arthroplasty. Recently, late appearances of adverse reactions to metal debris and subsequent need for reoperations have been reported with small-diameter head metal-on-metal devices. We retrospectively investigated mid-term clinical outcomes of small-head metal-on-metal total hip arthroplasty., Methods: We reviewed 159 hips in 139 patients who had a small-head metal-on-metal total hip arthroplasty (M2a Taper; Biomet, Warsaw, IN) with a minimum 5-year follow-up and documented postoperative complications., Results: Focal osteolysis in either the femur or acetabulum was observed in 12 hips (7.5%, 44 months after surgery on average), with pseudotumor observed in 8 hips (5%, 120 months after surgery on average). Four hips (2.5%) had dislocations (84 months after surgery on average) and six hips (3.8%, 122 months after surgery on average) underwent reoperation., Conclusion: Small-head metal-on-metal total hip arthroplasty is associated with a high degree of complications at mid-term follow-up period. Considering this, we discourage the use of metal-on-metal total hip arthroplasty regardless of head size., Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article., (© The Author(s) 2021.)
- Published
- 2021
- Full Text
- View/download PDF
11. Correction to: Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.
- Author
-
Arai Y, Ogawa M, Yamane F, Sumiyoshi N, Arimoto R, Ando Y, Endo D, Nakada T, Sugawara I, Yokoyama H, Shimoyama K, Inomata H, Kawahara Y, Kato M, Arihiro S, Hokari A, and Saruta M
- Published
- 2021
- Full Text
- View/download PDF
12. Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.
- Author
-
Arai Y, Ogawa M, Yamane F, Sumiyoshi N, Arimoto R, Ando Y, Endo D, Nakada T, Sugawara I, Yokoyama H, Shimoyama K, Inomata H, Kawahara Y, Kato M, Arihiro S, Hokari A, and Saruta M
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal adverse effects, Excipients adverse effects, Humans, Mesalamine adverse effects, Colitis, Ulcerative drug therapy, Hypersensitivity
- Abstract
Mesalazine formulations are essential for treating ulcerative colitis (UC), and intolerance to these formulations complicates the treatment of this condition. Some cases of mesalazine formulation intolerance are caused by the excipients rather than the active ingredient mesalazine. Therefore, mesalazine administration can be continued in such cases by changing the mesalazine formulation. This report describes a case of intolerance to mesalazine in which UC was effectively treated by switching mesalazine formulations. A drug-induced lymphocyte stimulation test suggested that allergy to the additive povidone was the cause of mesalazine formulation intolerance. This is the first case study to identify an additive that caused mesalazine formulation intolerance.
- Published
- 2020
- Full Text
- View/download PDF
13. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
- Author
-
Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, and Tamura T
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung etiology, Carcinoma, Non-Small-Cell Lung mortality, Clinical Trials, Phase II as Topic, Female, Humans, Japan, Kaplan-Meier Estimate, Lung Neoplasms etiology, Lung Neoplasms mortality, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Nivolumab administration & dosage, Nivolumab adverse effects, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Nivolumab therapeutic use
- Abstract
Background: Nivolumab is a programmed cell death 1 (PD-1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previously treated advanced squamous (SQ) and non-squamous (non-SQ) non-small cell lung cancer (NSCLC). We previously conducted two phase II studies of nivolumab in Japanese patients with SQ (ONO-4538-05) and non-SQ (ONO-4538-06) NSCLC, showing overall response rates (ORRs) (95% CI) of 25.7% (14.2-42.1) and 22.4% (14.5-32.9), respectively, with acceptable toxicity. In this analysis, we more precisely estimated the long-term safety and efficacy in patients with SQ and non-SQ NSCLC by pooling data from these two trials., Methods: SQ (N = 35) and non-SQ (N = 76) NSCLC patients received nivolumab (3 mg/kg, every 2 weeks) until progression or discontinuation. OS was estimated using the Kaplan-Meier method. A pooled analysis of SQ and non-SQ patients was also performed., Results: In SQ NSCLC patients, the median OS (95% CI) was 16.3 months (12.4-25.2), and the estimated 1-year, 2-year, and 3-year survival rates were 71.4% (53.4-83.5), 37.1% (21.6-52.7), and 20.0% (8.8-34.4), respectively. In non-SQ NSCLC patients, median OS was 17.1 months (13.3-23.0), and the estimated 1-, 2-, and 3-year survival rates were 68.0% (56.2-77.3), 37.4% (26.5-48.1), and 31.9% (21.7-42.5), respectively. When SQ NSCLC and non-SQ NSCLC data were pooled, the median OS was 17.1 months (14.2-20.6), and the estimated 1-, 2-, and 3-year survival rates were 69.1% (59.6-76.8), 37.3% (28.3-46.2), and 28.1% (20.0-36.7), respectively. Twenty (76.9%) of 26 responders lived for 3 or more years. Nivolumab was well tolerated and no new safety signals were found., Conclusion: Treatment with nivolumab improved long-term survival and was well tolerated in patients with SQ and non-SQ NSCLC., Trial Registration: JapicCTI-132072; JapicCTI-132073., (© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
14. Femoral neck fracture and central migration of the artificial femoral head after carbon ion radiotherapy for chondrosarcoma in the pelvis.
- Author
-
Sumiyoshi N, Torigoe T, Maezawa K, Narushima Y, Maruyama Y, Kaneko K, Imai R, and Kamada T
- Subjects
- Arthroplasty, Replacement, Hip adverse effects, Bone Neoplasms diagnostic imaging, Chondrosarcoma diagnostic imaging, Chondrosarcoma pathology, Chondrosarcoma surgery, Female, Femoral Neck Fractures diagnostic imaging, Follow-Up Studies, Foreign-Body Migration etiology, Heavy Ion Radiotherapy methods, Hip Prosthesis adverse effects, Humans, Middle Aged, Pelvis, Risk Assessment, Treatment Outcome, Arthroplasty, Replacement, Hip methods, Bone Neoplasms surgery, Chondrosarcoma radiotherapy, Femoral Neck Fractures etiology, Foreign-Body Migration diagnostic imaging, Heavy Ion Radiotherapy adverse effects
- Published
- 2018
- Full Text
- View/download PDF
15. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
- Author
-
Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, and Tamura T
- Subjects
- Aged, Asian People, Disease-Free Survival, Female, Humans, Male, Nivolumab, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Squamous Cell drug therapy, Lung Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Limited treatment options are available for stage IIIB/IV non-small cell lung cancer (NSCLC). Nivolumab, a programmed cell death-1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab in Japanese patients with advanced or recurrent squamous NSCLC that progressed after platinum-containing chemotherapy. In this multicenter phase II study, patients were treated with nivolumab (3 mg/kg, i.v.) every 2 weeks until progressive disease or unacceptable toxicity was seen. Primary endpoint was overall response rate (ORR) assessed by independent radiology review committee (IRC) and secondary endpoints included a study site-assessed ORR, overall survival (OS), progression-free survival (PFS), duration of response, time to response, best overall response (BOR), and safety. The study included 35 patients from 17 sites in Japan. Patients had IRC-assessed ORR of 25.7% (95% CI 14.2, 42.1) and the study site-assessed ORR was 20.0% (95% CI 10.0, 35.9). Median OS, median time to response and median PFS were 16.3 (95% CI 12.4-25.4), 2.7 (range 1.2-5.5) and 4.2 (95% CI 1.4-7.1) months, respectively. The IRC-assessed BOR was partial response, stable disease, and progressive disease for 25.7%, 28.6%, and 45.7% of patients, respectively. Treatment-related adverse events were reported in 24 patients (68.6%), most of which resolved with appropriate treatment including steroid therapy or discontinuation of nivolumab. Nivolumab was effective and well tolerated in Japanese patients with advanced or recurrent squamous NSCLC that progressed after platinum-containing chemotherapy., Clinical Trial Registration Number: JapicCTI-132072., (© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2017
- Full Text
- View/download PDF
16. Dysregulation of MAP Kinase Signaling Pathways Including p38MAPK, SAPK/JNK, and ERK1/2 in Cultured Rat Cerebellar Astrocytes Exposed to Diphenylarsinic Acid.
- Author
-
Negishi T, Matsumoto M, Kobayashi Y, Kojima M, Sakaguchi F, Takahata K, Kanehira T, Arakaki R, Aoyama Y, Yoshida H, Yamada R, Sumiyoshi N, Tashiro T, Hirano S, Yoshida K, and Yukawa K
- Subjects
- Animals, Astrocytes enzymology, Blotting, Western, Cells, Cultured, Cerebellum cytology, Cerebellum enzymology, Immunoenzyme Techniques, Rats, Arsenicals pharmacology, Astrocytes drug effects, Cerebellum drug effects, MAP Kinase Signaling System drug effects
- Abstract
Diphenylarsinic acid (DPAA) was a major compound found in the arsenic poisoning incident that occurred in Kamisu, Ibaraki, Japan in 2003. People exposed to DPAA via contaminated well water suffered from several neurological disorders, including cerebellar symptoms. We previously reported that DPAA induces cellular activation in cultured rat cerebellar astrocytes, dose-dependent promotion of cell growth (low DPAA), cell death (high DPAA), and increased phosphorylation of mitogen-activated protein (MAP) kinases (p38MAPK, SAPK/JNK, and ERK1/2). Moreover, DPAA induces up-regulation of oxidative stress-counteracting proteins, activation of CREB phosphorylation, increased protein expression of c-Jun and c-Fos, and aberrant secretion of brain-active cytokines (MCP-1, adrenomedullin, FGF2, CXCL1, and IL-6). Here, we explored the role of MAP kinases in DPAA-induced activation of astrocytes using specific MAP kinase signaling inhibitors [SB203580 (p38MAPK), SP600125 (SAPK/JNK), SCH772984 (ERK1/2), and U0126 (MEK1/2, a kinase for ERK1/2)]. DPAA-induced activation of MAP kinases had little contribution to DPAA-induced cell growth and death. On the other hand, a power relationship among MAP kinases was also observed, in which p38MAPK suppressed DPAA-induced SAPK/JNK and ERK1/2 activation, whereas ERK1/2 and MEK1/2 facilitated p38MAPK and SAPK/JNK activation. In addition, SAPK/JNK had minimal effects on the activation of other MAP kinases. DPAA-induced activation of transcription factors and secretion of brain-active cytokines were submissively but intricately dominated by MAP kinases. Collectively, our results indicate that DPAA-induced activation of MAP kinases is neither a cell growth-promoting response nor a cytoprotective one but leads to transcriptional disruption and aberrant secretion of brain-active cytokines in cerebellar astrocytes., (© The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
17. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.
- Author
-
Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, and Tamura T
- Abstract
Objective: Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC., Methods: In this multicentre phase II study, patients with advanced or recurrent non-squamous NSCLC, which had progressed after platinum-containing chemotherapy, were treated with nivolumab 3 mg/kg, intravenously every 2 weeks until progressive disease or unacceptable toxicity was observed. The primary end point was independent radiology review committee (IRC) assessed overall response rate (ORR) and the secondary endpoints included ORR (investigator assessed), progression-free survival (PFS), overall survival (OS), duration of response, time to response, best overall response, and safety., Results: 76 patients were enrolled across 19 sites in Japan. The ORR (IRC assessed) was 22.4% (95% CI 14.5% to 32.9%). The median PFS and OS were 2.8 months (95% CI 1.4 to 3.4) and 17.1 months (95% CI 13.3 to 23.0), respectively. The OS rate at 1 year was 68.0% (95% CI 56.2% to 77.3%). Current/former smokers were more responsive to treatment than non-smokers (ORR 29.1% vs 4.8%). Patients with epidermal growth factor receptor (EGFR) mutation wild type/unknown showed higher ORR compared with EGFR mutation-positive patients (ORR 28.6% vs 5.0%) and programmed cell death ligand-1 (PD-L1) expression was likely associated with higher ORR, longer PFS and OS. Treatment-related adverse events of grade 3 or higher were reported in 17 patients; these events resolved or were resolving with appropriate treatment including steroid therapy or discontinuation of nivolumab., Conclusions: Nivolumab was well tolerated and showed clinical efficacy in Japanese patients with non-squamous NSCLC progressed after platinum-containing chemotherapy, especially in those with a history of smoking, wild type/unknown EGFR mutation status or positive PD-L1 expression., Trial Registration Number: JapicCTI-132073., Competing Interests: Competing interests: MN received honoraria from Pfizer, Bristol-Myers Squibb, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical and AstraZeneca. MN also has been a consultant/advisor for Novartis, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, Pfizer, Bristol-Myers Squibb and Daiichi Sankyo, and received research funding from Novartis, Ono Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Eli Lilly, Pfizer, Astellas Pharma and AstraZeneca. THid received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Novartis, Taiho Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb and Clovis. THid also received research funding from Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Novartis, Taiho Pharmaceutical, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Clovis, Eisai, Takeda Pharmaceutical, Dainippon Sumitomo Pharma, Abbvie, Merck Serono, Kyowa Hakko Kirin, Daiichi Sankyo and Astellas Pharma. SA received honoraria from Chugai Pharmaceutical, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, and Bristol-Myers Squibb. SA also received funding from AstraZeneca and Taiho Pharmaceutical for participating in a speakers' bureau. SA also received research funding from Chugai Pharmaceutical, Pfizer, Ono Pharmaceutical, Merck Serono, Boehringer Ingelheim, AstraZeneca, Taiho Pharmaceutical, Yakult and Eli Lilly. HSakai received honoraria and funding to participate in a speakers' bureau from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly and Bristol-Myers Squibb. KN received honoraria from Astellas Pharma, AstraZeneca, EPS Holdings, Ono Pharmaceutical, Kyowa Hakko Kirin, Showa Yakuhin Kako, SymBio Pharmaceuticals, Daiichi Sankyo, Chugai Pharmaceutical, Boehringer Ingelheim, Eli Lilly, Pfizer and Bristol-Myers Squibb. KN also received research funding from Chugai Pharmaceutical, MSD, Ono Pharmaceutical, EPS Associates, Quintiles, Daiichi Sankyo, Japan Clinical Research Operations, Eisai, PPD-SNBL, Pfizer, Takeda Pharmaceutical, Boehringer Ingelheim, Taiho Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Kyowa Hakko Kirin and OncoTherapy Science. TTak received honoraria from AstraZeneca, Boehringer Ingelheim, Pfizer, Eli Lilly, Chugai Pharmaceutical and Ono Pharmaceutical. TTak also received research funding from AstraZeneca, Eli Lilly, Chugai Pharmaceutical, Ono Pharmaceutical, Pfizer, Takeda Pharmaceutical, Taiho Pharmaceutical and MSD. NN received honoraria from Astellas Pharma, AstraZeneca, Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Boehringer Ingelheim and Pfizer. HSaka received research funding from AstraZeneca, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly, Bayer, Taiho Pharmaceutical, MSD, Linical, Bristol-Myers Squibb and Sanofi. MT received honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Kyowa Hakko Kirin, Ono Pharmaceutical and Taiho Pharmaceutical. MT also received research funding from Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Boehringer Ingelheim, Novartis and Ono Pharmaceutical. MM received honoraria from AstraZeneca, Chugai Pharmaceutical, Pfizer, Ono Pharmaceutical, Bristol-Myers Squibb and Eli Lilly. MM also received research funding from Boehringer Ingelheim. YO’s immediate family member is an employee of Chugai Pharmaceutical. YO also has an immediate family member with an ownership of interest with Ono Pharmaceutical. YO received honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi Sankyo, Nippon Kayaku, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho Pharmaceutical, Clovis and Sanofi. YO has also been a consultant/advisor for AstraZeneca, Chugai Pharmaceutical Co., Eli Lilly, Ono Pharmaceutical and Novartis, and received funding from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Bristol-Myers Squibb, Kyorin Pharmaceutical, Dainippon Sumitomo Pharma, Pfizer, Taiho Pharmaceutical, Novartis and Merck Serono. YO has also been paid by AstraZeneca to provide expert testimony. HN received honoraria from AstraZeneca, Ono Pharmaceutical, Eli Lilly, Bristol-Myers Squibb and Chugai Pharmaceutical. HN also received research funding from Merck Serono, Pfizer, Taiho Pharmaceutical, Eisai, Chugai Pharmaceutical, Eli Lilly, Novartis, Daiichi Sankyo, GlaxoSmithKline, Yakult, Quintiles, Astellas Pharma, AstraZeneca, Boehringer Ingelheim and Ono Pharmaceutical. THir received research funding from MSD, AstraZeneca, Ono Pharmaceutical, Eisai, Daiichi Sankyo, Merck Serono, Eli Lilly, Taiho Pharmaceutical, Chugai Pharmaceutical, Kyowa Hakko Kirin and Takeda Pharmaceutical. HT received research funding from Eli Lilly, AstraZeneca, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Daiichi Sankyo, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical and Boehringer Ingelheim. KT received honoraria from AstraZeneca, Ono Pharmaceutical, Eli Lilly, Chugai Pharmaceutical, Taiho Pharmaceutical, Boehringer Ingelheim, Daiichi Sankyo and Kyowa Hakko Kirin. KT also has been a consultant/advisor for AstraZeneca, Eli Lilly and Novartis, and received research funding from AstraZeneca, Chugai Pharmaceutical, Eisai, Bristol-Myers Squibb, Eli Lilly, Ono Pharmaceutical, Kyowa Hakko Kirin, Boehringer Ingelheim and Merck Serono. KG received honoraria from Daiichi Sankyo, Nippon Kayaku, Kyowa Hakko Kirin, Bristol-Myers Squibb, AstraZeneca, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, Novartis, Eli Lilly and Boehringer Ingelheim. KG also has been a consultant/advisor for Taiho Pharmaceutical, Chugai Pharmaceutical, and Daiichi Sankyo, and received research funding from MSD, AstraZeneca, Taiho Pharmaceutical, Chugai Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, GlaxoSmithKline, OxOnc, Dainippon Sumitomo Pharma, Takeda Pharmaceutical, Novartis, Daiichi Sankyo, Kyowa Hakko Kirin, Astellas Pharma, Eisai, Eli Lilly, Amgen Astellas BioPharma, Pizer, Riken Genesis and Bristol-Myers Squibb. MS received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim Novartis and MSD. MS also received research funding from Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Novartis, MSD and Astellas Pharma. HI received funding to participate in a speakers' bureau from AstraZeneca, Bristol-Myers Squibb, Kyowa Hakko Kirin, Chugai Pharmaceutical and Boehringer Ingelheim. KM received research funding from Ono Pharmaceutical and Chugai Pharmaceutical. NS is an employee of Ono Pharmaceutical. TTam received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Boehringer Ingelheim, Eisai, Yakult, Novartis, Daiichi Sankyo and Astellas Pharma.
- Published
- 2017
- Full Text
- View/download PDF
18. The role of tetraspanin CD9 in osteoarthritis using three different mouse models.
- Author
-
Sumiyoshi N, Ishitobi H, Miyaki S, Miyado K, Adachi N, and Ochi M
- Subjects
- Age Factors, Animals, Cartilage, Articular metabolism, Cartilage, Articular pathology, Cell Line, Chondrocytes metabolism, Collagen Type II metabolism, Disease Models, Animal, Extracellular Matrix Proteins metabolism, Humans, Inflammation Mediators metabolism, Knee Joint metabolism, Knee Joint pathology, Mice, Mice, Knockout, Osteoarthritis etiology, Osteoarthritis pathology, Proteoglycans metabolism, Osteoarthritis genetics, Osteoarthritis metabolism, Tetraspanin 29 genetics, Tetraspanin 29 metabolism
- Abstract
Although osteoarthritis (OA) is the most prevalent aging-related joint disease, the understanding of mechanisms of OA pathogenesis remains limited. Key features include the progressive degradation of articular cartilage, synovial hyperplasia, and angiogenesis in joint tissues. CD9, a member of the tetraspanin family, is localized in the cell membranes and partly in the endosomes of all mammalian cell types. CD9 is associated with inflammation and angiogenesis through cell adhesion, migration, and signal transduction. This study examined the role of CD9 in OA development in three different mouse models: an aging model, a surgical model and antigen-induced arthritis (AIA) model, using CD9 deficient mice. Our study showed that CD9 deficiency reduced the severity of hallmarks of OA including cartilage degradation and soft tissue inflammation in aged mice. In the AIA model, cartilage damage and inflammation were also reduced in CD9
-/- mice. This was in contrast to the surgical OA model where disease severity was similar in wild-type and CD9-/- mice. Col2a1 and Aggrecan expression was increased in chondrocytes of CD9-/- mice compared with those of wild-type mice. Our results indicate that the suppression of cartilage degradation in CD9-/- could be in part related to an increase in the expression of the two main cartilage extracellular matrix proteins aggrecan and type II collagen.- Published
- 2016
- Full Text
- View/download PDF
19. Electrophysiological assessments of the motor pathway in diabetic patients with compressive cervical myelopathy.
- Author
-
Nakanishi K, Tanaka N, Kamei N, Hiramatsu T, Ujigo S, Sumiyoshi N, Rikita T, Takazawa A, and Ochi M
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Diabetes Mellitus, Type 2 complications, Female, Humans, Male, Middle Aged, Neural Conduction physiology, Spinal Cord Compression complications, Spinal Cord Compression surgery, Transcranial Magnetic Stimulation, Cervical Vertebrae, Diabetes Mellitus, Type 2 physiopathology, Evoked Potentials, Motor physiology, Spinal Cord Compression physiopathology
- Abstract
Object: The occurrence of compressive cervical myelopathy (CCM) increases in adults over 50 years of age. In addition, diabetes mellitus (DM) is a frequent comorbidity for people of this age and may impact the severity of CCM. The authors assessed motor pathway function in diabetic patients with CCM to investigate the correlation between electrophysiological parameters and clinical symptoms., Methods: Motor evoked potentials (MEPs) were measured from the abductor digiti minimi muscle (ADM) and the abductor hallucis muscle (AH) following transcranial magnetic stimulation, as were M- and F-waves following electrical stimulation of the ulnar and tibial nerves, in 22 patients with CCM and diabetes mellitus (DM) who had not experienced symptomatic diabetic neuropathy (CCM-DM group), in 92 patients with CCM alone (CCM group), and in 24 healthy adults (control group). The peripheral conduction time (PCT; measured from the ADM and AH) was calculated as follows: (M-wave latency + F-wave latency -1)/2. The central motor conduction time (CMCT; measured from the ADM and AH) was calculated by subtracting the PCT from the onset latency of the MEPs. The Japanese Orthopaedic Association (JOA) score for cervical myelopathy was obtained before and 1 year after surgery as a clinical outcome measure., Results: MEP, PCT, and CMCT parameters in the CCM-DM and CCM groups were significantly longer than those in the control group (p = 0.000-0.007). The PCTs in the CCM-DM group were significantly longer than those in the CCM group (p = 0.001-0.003). No significant differences were detected in the MEP and CMCT parameters between the CCM-DM and CCM groups (p = 0.080-1.000). The JOA score before surgery in the CCM-DM group was 10.7 ± 2.0 points and was significantly lower than that in the CCM group (12.2 ± 2.5 points, p = 0.015). In the CCM-DM group, JOA scores before surgery correlated with MEP-AH (r = -0.610, p = 0.012) and PCT-AH (r = -0.676, p = 0.004) values, but not with CMCT values, while the JOA scores were related to both MEP and CMCT parameters in the CCM group. The JOA scores improved to 13.8 ± 2.2 points after surgery (p = 0.001) and correlated with MEP-AH (r = -0.667, p = 0.005) and PCT-AH (r = -0.611, p = 0.012) in the CCM-DM group., Conclusions: The results suggest that MEP, PCT, and CMCT parameters each reveal abnormalities in the upper and lower motor neurons even in patients with DM. The results also show a prolonged PCT in CCM-DM patients, despite having no history of diabetic neuropathy. Corticospinal tract impairments are similar between CCM and CCM-DM patients, while the JOA score of the CCM-DM patients is lower than that in the CCM patients. The JOA score in CCM-DM patients may be influenced by additional impairments in peripheral nerves or other diabetic complications. These electrophysiological studies may be useful for screening motor pathway function for CCM in patients with DM.
- Published
- 2015
- Full Text
- View/download PDF
20. Activation of Yes-Associated Protein in Low-Grade Meningiomas Is Regulated by Merlin, Cell Density, and Extracellular Matrix Stiffness.
- Author
-
Tanahashi K, Natsume A, Ohka F, Motomura K, Alim A, Tanaka I, Senga T, Harada I, Fukuyama R, Sumiyoshi N, Sekido Y, and Wakabayashi T
- Subjects
- Cell Count, Cell Cycle Proteins, Cell Line, Tumor, Humans, Ki-67 Antigen metabolism, Meningeal Neoplasms pathology, Meningioma pathology, Nuclear Proteins genetics, Transcription Factors genetics, Gene Expression Regulation, Neoplastic physiology, Meningeal Neoplasms metabolism, Meningioma metabolism, Neurofibromatosis 2 metabolism, Neurofibromin 2 physiology, Nuclear Proteins metabolism, Transcription Factors metabolism
- Abstract
The NF2 gene product Merlin is a protein containing ezrin, radixin, and moesin domains; it is a member of the 4.1 protein superfamily associated with the membrane cytoskeleton and also interacts with cell surface molecules. The mammalian Hippo cascade, a downstream signaling cascade of merlin, inactivates the Yes-associated protein (YAP). Yes-associated protein is activated by loss of the NF2 gene and functions as an oncogene in meningioma cells; however, the factors controlling YAP expression, phosphorylation, and subcellular localization in meningiomas have not been fully elucidated. Here, we demonstrate that merlin expression is heterogeneous in 1 NF2 gene-negative and 3 NF2 gene-positive World Health Organization grade I meningiomas. In the NF2 gene-positive meningiomas, regions with low levels of merlin (tumor rims) had greater numbers of cells with nuclear YAP versus regions with high merlin levels (tumor cores). Merlin expression and YAP phosphorylation were also affected by cell density in the IOMM-Lee and HKBMM human meningioma cell lines; nuclear localization of YAP was regulated by cell density and extracellular matrix (ECM) stiffness in IOMM-Lee cells. These results suggest that cell density and ECM stiffness may contribute to the heterogeneous loss of merlin and increased nuclear YAP expression in human meningiomas.
- Published
- 2015
- Full Text
- View/download PDF
21. Blockade of gap junction hemichannel protects secondary spinal cord injury from activated microglia-mediated glutamate exitoneurotoxicity.
- Author
-
Umebayashi D, Natsume A, Takeuchi H, Hara M, Nishimura Y, Fukuyama R, Sumiyoshi N, and Wakabayashi T
- Subjects
- Animals, Excitatory Amino Acid Antagonists pharmacology, Female, Gap Junctions metabolism, Immunohistochemistry, Mice, Mice, Inbred C57BL, Reverse Transcriptase Polymerase Chain Reaction, Excitatory Amino Acids toxicity, Gap Junctions drug effects, Glutamic Acid toxicity, Heterocyclic Compounds, 4 or More Rings pharmacology, Microglia metabolism, Neuroprotective Agents pharmacology, Spinal Cord Injuries metabolism
- Abstract
We previously demonstrated that activated microglia release excessive glutamate through gap junction hemichannels and identified a novel gap junction hemichannel blocker, INI-0602, that was proven to penetrate the blood-brain barrier and be an effective treatment in mouse models of amyotrophic lateral sclerosis and Alzheimer disease. Spinal cord injury causes tissue damage in two successive waves. The initial injury is mechanical and directly causes primary tissue damage, which induces subsequent ischemia, inflammation, and neurotoxic factor release resulting in the secondary tissue damage. These lead to activation of glial cells. Activated glial cells such as microglia and astrocytes are common pathological observations in the damaged lesion. Activated microglia release glutamate, the major neurotoxic factor released into the extracellular space after neural injury, which causes neuronal death at high concentration. In the present study, we demonstrate that reduction of glutamate-mediated exitotoxicity via intraperitoneal administration of INI-0602 in the microenvironment of the injured spinal cord elicited neurobehavioral recovery and extensive suppression of glial scar formation by reducing secondary tissue damage. Further, this intervention stimulated anti-inflammatory cytokines, and subsequently elevated brain-derived neurotrophic factor. Thus, preventing microglial activation by a gap junction hemichannel blocker, INI-0602, may be a promising therapeutic strategy in spinal cord injury.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.